I'll follow up on Mr. Keon's remarks on the linkage system, the patented medicine notice of compliance system. It's not a perfect system from either the generic or the brand perspective, but I will agree that it's a strong system. I must say I'm a bit annoyed that we're on the U.S. watch list on the patent side because of that. This has been such an issue with the Europeans. Arguably, this aspect of our patent system is stronger than the corresponding aspect in the U.S. or Europe.
It's difficult because the details matter. It's difficult to say, but it is important that we look at the NOC system, the patent system as a whole, and decide whether we have a strong system or a weak system. Can we improve it in the details? For sure, but at the trade negotiation level it's not really fair for anyone to be saying they don't like this or that and therefore the whole system is wrong. We have to look at the system as a whole.